MoonLake Immunotherapeutics (NASDAQ:MLTX) and Acurx Pharmaceuticals (NASDAQ:ACXP) Critical Contrast

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares MoonLake Immunotherapeutics and Acurx Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%
Acurx Pharmaceuticals	N/A	-153.92%	-101.69%

Insider and Institutional Ownership

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 12.1% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares MoonLake Immunotherapeutics and Acurx Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32 million	($3.87)	-4.88
Acurx Pharmaceuticals	N/A	N/A	-$7.97 million	($4.05)	-0.47

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -2.09, meaning that its share price is 309% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for MoonLake Immunotherapeutics and Acurx Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3	4	9	0	2.38
Acurx Pharmaceuticals	1	0	1	0	2.00

MoonLake Immunotherapeutics presently has a consensus price target of $23.85, suggesting a potential upside of 26.30%. Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 1,523.04%. Given Acurx Pharmaceuticals’ higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than MoonLake Immunotherapeutics.

Summary

MoonLake Immunotherapeutics beats Acurx Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.